Semaglutide vs Tirzepatide: What the Evidence Shows
Tirzepatide produced larger weight loss in trials (up to ~21% vs ~15%); semaglutide has the longer cardiovascular-outcomes record and an oral option. An independent, evidence-based comparison.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
For weight loss, tirzepatide produced larger average loss in trials (up to about 21% versus about 15% for semaglutide), while semaglutide has the longer cardiovascular-outcomes track record and an oral option. Both are FDA-approved and Grade A; the better choice depends on the goal, tolerability, and cost, and is a clinician's decision.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Avg weight loss (trials) | ~15% (STEP 1, 2.4 mg) | Up to ~21% (SURMOUNT-1) |
| Also approved for | Type 2 diabetes, cardiovascular risk reduction | Type 2 diabetes, obstructive sleep apnea |
| Formulations | Weekly injection, plus oral (Rybelsus) | Weekly injection |
| Tolerability | Mostly GI; thyroid C-cell boxed warning | Mostly GI; thyroid C-cell boxed warning |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
Weight loss: tirzepatide leads
Across their pivotal trials, tirzepatide produced the larger average weight loss: up to roughly 21% at the highest dose in SURMOUNT-1, versus about 15% for semaglutide at 2.4 mg in STEP 1. These were separate trials, not a head-to-head, and individual results vary, but the gap is consistent enough that tirzepatide is generally considered the more powerful weight-loss agent. Its dual action on both the GIP and GLP-1 receptors is the leading explanation.
Where semaglutide counters
Semaglutide has two advantages tirzepatide does not currently match. First, the SELECT trial demonstrated cardiovascular risk reduction in people with overweight or obesity and established heart disease, a hard clinical outcome. Second, semaglutide has an oral option (Rybelsus), which matters for anyone reluctant to inject. Tirzepatide, in turn, is also FDA-approved for obstructive sleep apnea, an indication semaglutide does not hold.
Tolerability is similar
Both are titrated slowly to manage gastrointestinal side effects, which are the most common complaint for each. Both carry the same boxed warning for thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Neither is a clear winner on safety.
Bottom line
Tirzepatide edges out semaglutide on raw weight loss in the trial data. Semaglutide counters with proven cardiovascular risk reduction (SELECT) and an oral formulation. Both are Grade A, FDA-approved, and prescription-only, so the right pick is individual, not universal.
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?+
In trials, tirzepatide produced more weight loss on average (up to about 21% versus about 15%). But the trials were separate, results vary, and semaglutide has advantages like proven cardiovascular benefit and an oral option.
Which has fewer side effects, semaglutide or tirzepatide?+
Their side-effect profiles are similar, mostly gastrointestinal, and both carry the same thyroid boxed warning. Neither is clearly better tolerated.
Can you switch from semaglutide to tirzepatide?+
Switching is common and is done under clinician supervision with re-titration. This is a medical decision based on response, tolerability, and access, not something to self-manage.
Sources
- 1.Drugs@FDA: FDA-Approved Drugs database · U.S. Food & Drug Administration
- 2.Jastreboff AM et al. Tirzepatide Once Weekly for Obesity (SURMOUNT-1), NEJM 2022 · New England Journal of Medicine
- 3.Wilding JPH et al. Once-Weekly Semaglutide in Overweight or Obesity (STEP 1), NEJM 2021 · New England Journal of Medicine